Professor Augusto Pessina Brief CV



Similar documents
Drug Development Services

Ariela Benigni. Biol.Sci.D., Ph.D. Curriculum Vitae

Curriculum Vitae of Luca Gianni

The haematotoxic potential of xenobiotics is determined by the evaluation of the inhibition of CFU-GM growth.

Future Oncology: Technology, Products, Market and Service Opportunities

Basic Overview of Preclinical Toxicology Animal Models

Fee-for-service cores for Investigational New Drug enabling studies

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

A Genetic Analysis of Rheumatoid Arthritis

CONTENT. Chapter 1 Review of Literature. List of figures. List of tables

How To Expand Hematopoietic Stem Cells

Do you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life

JUMISC JUMISC. For further information visit our website:

Biotechnology. Srivatsan Kidambi, Ph.D.

How To Treat Mesothelioma With A Tumor Stem Cell Inhibitor

Stem Cell Quick Guide: Stem Cell Basics

The Need for a PARP in vivo Pharmacodynamic Assay

Evaluation of focal adhesions as new therapeutic targets in acute myeloid leukemia

Micromyx. Micromyx. A Microbiology Services Company. Lab Services Research - Consulting -

GRANIX (tbo-filgrastim)

Stem cells possess 2 main characteristics: Sources of pluripotent stem cells: -Long-term self renewal. -The inner cell mass of the blastocyst.

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

MAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères Evry Cedex. is involved at each stage of your project

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research

STEM CELL FELLOWSHIP

The role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015

Nuevas tecnologías basadas en biomarcadores para oncología

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist

How To Understand The Effects Of A Drug On Your Health

Cytotoxic and Biotherapies Credentialing Programme Module 2

AAGPs TM Anti-Aging Glyco Peptides. Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule

Notch 1 -dependent regulation of cell fate in colorectal cancer

Griffith University - Case for Support. Mesothelioma Research Program

5 Frequently Asked Questions About Adult Stem Cell Research

Roche Position on Human Stem Cells

MATHEMATICAL MODELS OF TUMOR GROWTH INHIBITION IN XENOGRAFT MICE AFTER ADMINISTRATION OF ANTICANCER AGENTS GIVEN IN COMBINATION

Basic Science in Medicine

Disclosure. Gene Therapy. Transfer of genes into cells Expression of transferred genes

Support Program for Improving Graduate School Education Advanced Education Program for Integrated Clinical, Basic and Social Medicine

CURRICULUM VITAE ROBERTO GIACOMELLI MD, PhD

Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center

Activation and effector functions of HMI

The Therapeutic Potential of Human Umbilical Cord Blood Transplantation for Neonatal Hypoxic-Ischemic Brain Injury and Ischemic Stroke

Immuno-Oncology Model Application in the Preclinical Treatment Setting

Session 6 Clinical Trial Assessment Phase I Clinical Trial

Human Umbilical Cord-derived Multipotent Mesenchymal Stromal Cells (huc-msc) Handling Instructions

Newborn Stem Cells from Cord Blood and the Brain: Repairing Injury and Improving Function

FGF-1 as Cosmetic Supplement

STEM CELL FACTS. The ISSCR is an independent, nonproft organization providing a global forum for stem cell research and regenerative medicine.

Stem Cells and Inner Ear Cell Regeneration. Stefan Heller Stanford University School of Medicine

Date and place of birth 28th January 1958; Moretta (Cuneo) (Italy). Two children

The immune system. Bone marrow. Thymus. Spleen. Bone marrow. NK cell. B-cell. T-cell. Basophil Neutrophil. Eosinophil. Myeloid progenitor

Non-clinical development of biologics

MDM. Metabolic Drift Mutations - Attenuation Technology

Stem cells for brain cures

Course Descriptions. I. Professional Courses: MSEG 7216: Introduction to Infectious Diseases (Medical Students)

Future Health Technologies. From Academia to Industry The Stem Cell Challenge. Roger J. Dainty MBE FIScT UK Managing Director

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking

Complex Systems BioMedicine: Molecules, Signals, Networks, Diseases

Additional file 1. Progress of phase II clinical trials of Panagen

Saving Your Baby s Cord Blood

FACULTY OF ALLIED HEALTH SCIENCES

LESSON 3.5 WORKBOOK. How do cancer cells evolve? Workbook Lesson 3.5

Targeted Therapy What the Surgeon Needs to Know

Curriculum Vitae - Sara Gandini

Publikationsliste Claudia Götz

La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi

An Overview of Cells and Cell Research

Luca Romagnoli, Ph.D. Business Development Manager

Equine Stem Cells. Sources, Processing, Expansion, Storage and Shipping

Support structure for genetic material

Curriculum Vitae. Education: Research Associate (Sept Current)

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE PRE-CLINICAL EVALUATION OF ANTICANCER MEDICINAL PRODUCTS

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

A Local Stability of Mathematical Models for Cancer Treatment by Using Gene Therapy

Umbilical Cord Blood Stem Cells Current Status & Future Potential

Immuno-Oncology Therapies to Treat Lung Cancer

Microbiology AN INTRODUCTION EIGHTH EDITION

FACULTY OF MEDICAL SCIENCE

Stem Cell Information

Course Curriculum for Master Degree in Clinical Pharmacy

Rome, 9-10 June 2016

27 th. Annual Conference. 27 th Annual Conference of Italian Association of Cell Cultures (ONLUS-AICC)

The Types of stem cells: Totipotent Pluripotent Multipotent

Scientific Programme

So, get comfortable and enjoy finding out what the greatest achievements and challenges are facing the industry today.

The use of monoclonal antibodies in the setting of HSCT

National Workshop of Hematology The TP53 Workshop

Stem cells and motor neurone disease

Fighting the Battles: Conducting a Clinical Assay

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Custom Antibody Services

Monoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.

Chemotherapy resistance in acute myeloid leukemia: the role of adhesion

Chapter 8. Summary and Perspectives

Development of the Anti- Parasitic Drug Mebendazole for High Grade Glioma Therapy

An Introduction to Stem Cell Biology. Michael L. Shelanski, MD,PhD Professor of Pathology and Cell Biology Columbia University

Chapter 16 Reproductive Technology, Gene Therapy, and Stem Cells (modified)

On the origin of giant multinuclear Reed-Sternberg cells and the role of CD4 T cells in Hodgkin lymphoma

Transcription:

Professor Augusto Pessina Brief CV Present Position Associated Professor Professor of Microbiology Faculty of Medicine of the University of Milan. Head of Cell Culture Laboratory,Section of Microbiology, Department of Biomedical Surgical and Dental Sciences.President Gruppo Italiano Staminali Mesenchimali (GISM).Past President: Associazione Italiana di Colture Cellulari (AICC) Teaching and research: Graduated in Biological Science,University of Milan (1971). Specialized in Medical Microbiology, University of Milan (1978).Assistant Researcher at Centre of Cellular Pathology of the National Council for Research, Milan (1973-1976).Selected as Italian Participant to the Second training course on experimental cancer research of UICC (Amsterdam,1975).Appointed by the National Board of Education of Italy to the Department of Pathology, Hospital of Desio for studying the effect of Dioxine (TCDD) on immune system of children accidentally exposed to the toxic in Seveso (1976-1981). Professor of General Pathology at School of Pharmacology, Faculty of Pharmacy, University of Milan.(1982-1985). Appointment by the Board of Education to the Institute of Medical Microbiology, University of Milan for developing new educational training (1981-1988). External Examiner for PhD thesis at the School of Biological Sciences, National Cell and Tissue Culture Centre Dublin City University (Ireland) (1994,2011).Reporter of a PhD thesis at the Universitè de Bretagne Occidentale (UBO) France(2004). Management of scientific events Organizer and promoter of many national and international scientific events as congress, meeting, workshop and courses.co-organizer with Prof. Martin Clynes ( Dublin City University-Ireland) of the "First International Meeting on Drug Resistance in Cancer" (1995).Representative of the division "Cancer sensitivity and drug resistance" of the European Tissue Culture Society (ETCS) (1994-1998). Chairman of the Italian Committee of the 3 rd World Congress on Alternatives and Animal use in life science. Bologna 1999.Member of the Scientific Advisory Board of the National Institute for Cellular Biotechnology (NICB) of Dublin City University ( Ireland) (2001-2005).Co- President of the 46P thp ETCS meeting held in Verona ( 2006).President of the Italian Association for Cell Culture (AICC) ( 2007-2010).Member of the International Scientific Societies and peer reviewer of may international scientific journals. Scientific responsible of the following European Commission projects: In vitro system for testing haematotoxicity (1994-1996). Inhibition of CFU-E/BFU-E by different classes of chemicals: a comparative study on direct effects on progenitors and the effect on longterm exposure of bone marrow (1997-1998). In vitro tests for haematotoxicity: prevalidation and validation of GM-CFU assay for predicting acute neutropenia (1997-2001). Development and prevalidation of the in vitro assays for the prediction of thrombocytopenia (Italian Operative Unit 2000-2002) Purification and regulation of haematopoietic stem cells: in vitro studies (2001-2002)."Plasticity of adult stem cells in cord blood" (2002-2003) Prevalidation of rat CFU-GM assay ( 2006-2008) Scientific Unit Responsible inside the projects Transplant of adult stem cells in regenerative cellular therapy of Blood Plan of Regione Lombardia ( 2006-2008). Role of human mesenchymal stem cells in tumor angiogenesis of AIRC ( Associazione Italiana per la Ricerca sul Cancro) ( 2010-2012). LoCMeD - Lab on Chip for testing Myelotoxic effect of Drugs and chemicals (Fund from Fondazione Cariplo) (2011-2013). " Mesenchymal stromal cells loaded with Paclitaxel home glioblastoma vasculature and inhibit tumor growth of AIRC ( Associazione Italiana per la Ricerca sul Cancro) ( 2013-2016) 1

Some notes on research activity particularly related to hematotoxicity The experience of Dr Augusto Pessina in the field of hematotoxicity originated in the years 1970 with studies concerning the relation between the neoplastic growth and the haematopoietic disorders observed in tumor bearing mice. He developed specific in vitro techniques for studying the effect exerted by factors produced by tumor cells on the proliferation and differentiation of myeloid precursors and in his laboratory were isolated cytokines active on the haematopoietic progenitors (Int. J. Immunopharmacol. 7,549,1985; Blut,55,499,1987). At the first UICC training course organized in Amsterdam on 1975 had as teacher Donald Melcalf (who is considered the pioneer of the in vitro studies on proliferation and differentiation of haematopoietic progenitors) and the possibility to improve the techniques for assessing the "in vitro" growth of granulocyte-macrophage committed cells (GM-CFU). Dr. Pessina has been involved five years (1976-1981)in an international project at the Hospital of Desio (Milan,Italy) for studying the haematotoxic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on the immune system of children accidentally exposed to the toxic in the area of Seveso ( ICMESA accident). Since 1981 he runs a Laboratory of Cell Culture at the Institute of Microbiology (Milan) and his researches have been continued on the relationship between tumor growth and the production of cytokines ( CSFs) involved in the proliferation- differentiation of pluripotent stem cells ( CFU-s) and committed progenitors ( CFU-C) in haematopoiesis ( J. Cancer Res.Clin. Oncol.,102,235,1982; Oncology 39,391,1982; J.Natl.Cancer Inst., 76,1095,1986). In his laboratory have been established twi new cell lines: a stromal cell line obtained from murine bone marrow adherent cells (SR-4987), ( Cytotechnology 8,93,1992 ) available by ATCC (CRL-2028) and a subclone of WEHI-3B leukemia cells resistant to ciprofloxacin ( Cancer J.,6,291,1993) due to a mutation of topoisomerase II. By using SR-4987 cells has been standardized a new "in vitro" method for testing FGFs in biological samples and developed an in vitro model to investigate the role of stromal cells in the modulation of drug induced hematotoxicity (Life Sci.,65,513,1999). Researches of the response of different cellular models the biological effects of microbial toxins demonstrated that the proliferative block exerted by Cholera Toxin may be dependent or not to the camp accumulation and that there are membrane ganglioside with different affinity to CT ad capacity to transduce the signal. A stable mutant of a leukemia cell line (WEHI-3B) has been established by Dr Pessina which lacks of the Gal-GalNac-GM1b ganglioside that is a very important functional receptor in WEHI-3b cells ( Cell.Mol.Biol.,44,933-940,1998. Mol.Cell.Biochem,152,103-112,1995 Mol.Cell Biochem. 233,19-26, 2002) By using GM-CFU techniques Dr Pessina studied the effect of topoisomerase inhibitors, antibiotics and microbial toxins on different animal cell models ( J.Antimicrob. Chemother., 24,203,1989; Biochim.Bioph. Acta,1013,206,1989 ; Mol. Cell Biochem.,152,1995). Since 1994 he managed EC contracts concerning the development of alternative methods for hematototoxicity testing and coordinated projects of prevalidation and validation of standard operating procedure based on the use of multipotent stem cells as progenitors of granulocyte-macrophages (GM- CFU), megakaryocytes (Mk-CFU) and erythrocytes (CFU-E). Based on these results ( Toxicological Sciences, 75,355-367,2003 ) the ECVAM Scientific Advisory Committee (ESAC) on 2006 unanimously endorsed the CFU-GM assay for predicting acute neutropenia in humans. Recently a study has been conducted to prevalidate the GM-CFU assay with frozen bone marrow cells of rat that can contribute to REACH programme ( Altern.To Lab.Animals 37: 417-425,2009. Altern.To Lab.Animals 38:105-117,2010). Since 2004 the cell culture laboratory of Dr Pessina is involved in studies on the therapeutic potential of stem cells and on assays to assess their safety with a particular attention to the microbiological risks (BBRC, 323:315-322,2004, Crit.Rev.Microbiol, 34:1-12,2008,Transpl Infect Dis.11 : 491-496,2009 ;,Cell Biol. Int. 34:783-790,2010). More recent his group have indicated that MSCs can be used as drug carrier. By using a cancer drug ( Paclitaxel) has been demonstrated that human MSCs are able to uptake and release the drug and that PTX loaded MSCs produced a dramatic inhibition of tumor growth both in vitro and in vivo. PLoS ONE 6(12): e28321. doi:10.1371/journal.pone.0028321. In recent paper his laboratori demonstrated that drugs can be released by mesenchymal stem cells into 2

microvesicles/exosomes opening new possible biotechnology application for the production of more bioavailable molecules able to support new therapeutic approaches. 2014-2010 A selection of some publications of the last 15 years 1999-2014. PASCUCCI L, COCCÈ V, BONOMI A, AMI D, CECCARELLI P, CIUSANI E, VIGANÒ L, LOCATELLI A, SISTO F, DOGLIA SM, PARATI E, BERNARDO ME, MURACA M, ALESSANDRI G, BONDIOLOTTI G, PESSINA A. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. Journal Controlled Release 192: 262-270, 2014. SISTO F, BONOMI A, CAVICCHINI L, COCCÈ V, SCALTRITO MM, BONDIOLOTTI G, ALESSANDRI G, PARATI E, PESSINA A. Human mesenchymal stromal cells can uptake and release ciprofloxacin, acquiring in vitro anti-bacterial activity. Cytotherapy. 2014,16:181-90. MARIOTTI M, COLOGNATO R, RIMOLDI M, RIZZETTO M, SISTO F, COCCE V, BONOMI A, PARATI E, ALESSANDRI G, BAGNATI R, PESSINA A. Mesenchymal Stromal Cells Uptake And Release Paclitaxel Without Reducing Its Anticancer Activity. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol. 13, p. 523-530, ISSN: 1871-5206, doi: 10.2174/1871520611313030015 S. NAVONE, L. PASCUCCI, M. DOSSENA, A. FERRI, G. INVERNICI, F. ACERBI, S. CRISTINI, G. BEDINI, V. TOSETTI, V. CESERANI, A. BONOMI, A. PESSINA, G. FREDDI, A. ALESSANDRINO, P. CECCARELLI, R. CAMPANELLA, G. MARFIA, G. ALESSANDRI, E.A. PARATI (2014). Decellularized silk fibroin scaffold primed with adipose mesenchymal stromal cells improves wound healing in diabetic mice. STEM CELL RESEARCH & THERAPY, vol. 5, p. 1-15, ISSN: 1757-6512, doi: 10.1186/scrt396 ANTONELLA CONFORTI, SIMONE BIAGINI, NADIA STARC, ALESSANDRA PROIA,AUGUSTO PESSINA, GIULIO ALESSANDRI, FRANCO LOCATELLI, MARIA ESTER BERNARDO. Human mesenchymal stromal cells primed with paclitaxel, apart from displaying anti-tumor activity, maintain their immune regulatory functions in vitro. Cytotherapy, 2014; 16: 868e870 pen Access LUIGI BALDUCCI, ANTONELLA BLASI, MARILISA SALDARELLI, ANTONIO SOLETI, AUGUSTO PESSINA, ARIANNA BONOMI,VALENTINA COCCÈ, MARTA DOSSENA, VALENTINA TOSETTI, VALENTINA CESERANI, STEFANIA ELENA NAVONE,MARIA LAURA FALCHETTI, EUGENIO AGOSTINO PARATI AND GIULIO ALESSANDRI. Immortalization of human adipose-derivedstromal cells: production of cell lines with highgrowth rate, mesenchymal marker expression andcapability to secrete high levels of angiogenic factors. Stem Cell Research & Therapy 2014, 5:63 M. RASPONI, A. GAZANEO, A. BONOMI, P. OCCHETTA, L. CAVICCHINI, V. COCCE, G. B. FIORE, A.PESSINA AND A. REDAELLI. Lab-on-Chip for testing Myelotoxic effect of drugs and chemicals GNB2014, June 25th-27th 2014, Pavia, Italy. PESSINA A, COCCÈ V, PASCUCCI L, BONOMI A, CAVICCHINI L, SISTO F, FERRARI M, CIUSANI E, CROVACE A, FALCHETTI ML, ZICARI S, CARUSO A, NAVONE S, MARFIA G, BENETTI A, CECCARELLI P, PARATI E, ALESSANDRI G. Mesenchymal stromal cells primed 3

with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice. Br J Haematol. 2013; 160: 766-78. BONOMI A, COCCÈ V, CAVICCHINI L, SISTO F, DOSSENA M, BALZARINI P, PORTOLANI N, CIUSANI E, PARATI E, ALESSANDRI G, PESSINA A. Adipose-tissuederived stromal cells primed in vitro with paclitaxel acquires anti-tumor activity. Int J Immunopathol Pharmacol. 2013:26,33-41. PESSINA A, BONOMI A, CIUSANI E, PASCUCCI L, PARATI E, ALESSANDRI G. Mesenchymal stromal cells used for carrying and delivering Paclitaxel in Paclitaxel: Biosynthesis, Mechanisms of Action and Clinical Uses, D. Morales, Nova Science Publishers 2013, pp 141-157. PESSINA A, BONOMI A, PARATI E, PALLINI R, ALESSANDRI G. Primed mesenchymal stromal cells for cancer therapy. In Stem Cell Therapeutics for Cancer. Ed Khalid Shah, Wiley Blackwell 2013, pp 189-204. LAURA DE GIROLAMO, ENRICO LUCARELLI2, GIULIO ALESSANDRI3, MARIA ANTONIETTA AVANZINI4, MARIA ESTER BERNARDO,ETTORE BIAGI, ANNA TERESA BRINI, GIOVANNA D AMICO, FRANCA FAGIOLI, IVANA FERRERO10, FRANCO LOCATELLI,RITA MACCARIO, MARIO MARAZZI, ORNELLA PAROLINI, AUGUSTO PESSINA AND MARIA LUISA TORRE. Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm.Efficacy and Critical Aspects in Cell Therapy. Current Pharmaceutical Design, 2013, 19, 2459-2473 S. DUCHI, P. DAMBRUOSO,E. MARTELLA,G. SOTGIU,A. GUERRINI, E. LUCARELLI,A. PESSINA,V. COCCÈ,A. BONOMI,AND G. VARCHI. Thiophene-Based Compounds as Fluorescent Tags to Study Mesenchymal Stem Cell Uptake and Release of Taxanes BIOCONJUGATE CHEMISTRY, vol. 25, p. 649-655, ISSN: 1043-1802, doi: 10.1021/bc5000498 AUGUSTO PESSINA,VALENTINA COCCÈ, ARIANNA BONOMI, LOREDANA CAVICCHINI, FRANCESCA SISTO, MAURA FERRARI,EMILIO CIUSANI, STEFANIA NAVONE, GIOVANNI MARFIA, EUGENIO PARATI AND GIULIO ALESSANDRI. Human Skin-Derived Fibroblasts Acquire In Vitro Anti-Tumor Potential after Priming with Paclitaxel.Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 523-30. PESSINA A.,SISTO F.,COCCE V.,CAVICCHINI L.,CIUSANI E.,GRIBALDO L., BONOMI. A mesenchymal stromal cell line resistant to paclitaxel that spontaneously differentiates into Osteoblast-like cells. Cell Biol Toxicol 27:169-180,2011. PESSINA A., BONOMI A, COCCÈ V, INVERNICI G, NAVONE S, CAVICCHINI L et al.. Mesenchymal Stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS ONE 6(12): e28321.doi:10.1371/journal.pone.0028321 (2011). PESSINA A.,BONOMI A.,CAVICCHINI L.,ALBELLA B., CERRATO L.,PARENT-MASSIN D.,SIBIRIL Y.,PARCHMENT R.,BEHRSING H.,VERDERIO P., PIZZAMIGLIO S.,GIANGRECO M., BAGLIO C.,COCCÈ V.,SISTO F. and GRIBALDO L..Prevalidation of Rat GM-CFU Assay for In Vitro Toxicology Application. Altern.To Lab.Animals (ATLA) 38:105-117,2010. PESSINA A., BONOMI A.,SISTO F., BAGLIO C., CAVICCHINI L.,CIUSANI L.,COCCÉ V., GRIBALDO L.. CD45+/CD133+ positive cells expanded from umbilical cord blood expressing pdx-1 and markers of pluripotency. Cell Biol. Int. 34:783-790,2010. 4

PESSINA A. Cellule staminali pluripotenti. Le prospettive delle ipsc restano problematiche Emmeciquadro 38: 27-30,2010. PESSINA A., BONOMI A. Prediction of potential drug myelotoxicity by in vitro assays on haematopoietic progenitors. In Methods in Bioengineering: Alternative technologies to animal testing" eds Tim Maguire and Eric Novik Eds,Artech House Boston-London. Pages 115-131,2010. LULLI M, DI GESUALDO F.,WITORT E.,PESSINA A.,CAPACCIOLI S.. Cell death: physiopathological and therapeutic implications. Cell Death Dis. 1: e30; doi: 10.1038/cddis.2010. 2009-2005 PESSINA A.,PARENT-MASSIN D., ALBELLA B.,VAN DEN HEUVEL R.,CASATI S.,CROERA C.,MALERBA I.,SIBIRIL Y.,GOMEZ.S., DE SMEDT.,GRIBALDO L.. Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs. Toxicology in Vitro, 23:194-200,2009. PESSINA A., BONOMI A., BAGLIO C., CAVICCHINI L., GRIBALDO Refinement and Optimisation of the rat CFU-GM assay to use cryopreserved bone marrow cells for in vitro toxicology application. Altern.To Lab.Animals (ATLA) 37: 417-425,2009. PESSINA A.,BONOMI A.,COCCÈ V., BERNARDO M.E., COMETA A.M., FERRARI M., SISTO F.,CAVICCHINI L.,LOCATELLI F. Assessment of human herpesvirus-6 infection in mesenchymal stromal cells ex vivo expanded for clinical use.transpl Infect DisT.11 : 491-496,2009. PESSINA A. BONOMI A., BAGLIO C.,CAVICCHINI L.,SISTO F., NERI MG.,GRIBALDO L..Microbiological Risk Assessment In Stem Cell Manipulation. Crit.Rev.Microbiol, 34:1-12,2008 PESSINA A., BONOMI A.,CASATI S.,COLLOTTA A.,CROERA C.,MARAFANTE E.,PALITTI F.,GRIBALDO L.. Mitochondrial function, apoptosis and cell-cycle delay in the WEHI-3B leukemia cell line and its variant ciprofloxacin-resistant WEHI-3B/CPX. Cell Prolif.,40,568-579,2007. PESSINA A., BONOMI A. CFU-GM assay for evaluation of drug Myelotoxic Activity Curr.Prot.Toxicol. 34:20.2.1-20.2.18, Eds. John Wiley & Sons,Inc., 2007. PESSINA A., TURLIZZI E., BONOMI A., GUIZZARDI F., CAVICCHINI L.,CROERA C., BAREGGI S..In vitro toxicity of clozapine,olanzapine and quetiapine on granulocyte-macrophage progenitors(gm- CFU). Pharmacopsychiatry,39,20-22,2006. PESSINA A., CROERA C.,SAVALLI N.,BONOMI A.,CAVICCHINI L.P 1P,TURLIZZI E., GUIZZARDI F.,GUIDO L.,DAPRAI L.,P 1P NERI MG..Bcl-2 down modulation in WEHI-3B/CTRES cells resistant to Cholera Toxin (CT)-induced apoptosis. Cell Res. 16:306-312,2006 PESSINA A., and GRIBALDO L..The key role of adult stem cells: therapeutic perspectives. Curr. Med. Res. Opin.,22,2287-2300,2006 PESSINA A., MALERBA I., GRIBALDO L. Haematotoxicity testing by cell clonogenic assay in drug development and preclinical trials Curr.Pharmaceut.Design 11,1055-1065,2005. 1999-2004 PESSINA A., CROERA C., BAYO M., MALERBA I., PASSARDI L., CAVICCHINI L., 5

NERI M.G., GRIBALDO L. A methylcellulose microculture assay for the in vitro assessment of drug toxicity on granulocyte- macrophage progenitors (CFU-GM). ATLA 32:17-23, 2004 PESSINA A.,ELETTI B.,CROERA C.,SAVALLI N.,DIODOVICH C.,GRIBALDO L.. Pancreas developing markers expressed on human mononucleated umbilical cord blood cells.biochem Biophys. Res. Comm. 323:315-322,2004 PESSINA A., ALBELLA B., BAYO M., BUEREN J.,.BRANTOM P., CASATI S.,. CROERA C.,GAGLIARDI G FOTI P, PARCHMENT R., PARENT-MASSIN D., SCHOETERS G., SIBIRIL Y.,VAN DEN HEUVEL R.,.GRIBALDO L. Application of the CFU-GM assay to predict acute drug-induced neutropenia:an international blind trial to validate a prediction model for the maximum tolerated dose(mtd) of myelosuppressive xenobiotics. Toxicological Sciences, 75,355-367,2003. ROSEEUW E.,COESSENS V.,BALAZUC AM.,LAGRANDERIE M.,CHAVAROT P., PESSINA A., NERI MG., SCHACHT E.,MARCHAL G., DOMURADO D.. Synthesis, degradation and antimicrobial properties of targeted macromolecular prodrugs of norfloxacin. Antimicrob. Agents Chemother.,47,3435-3441,2003. PESSINA A., BAYO M.,CROERA C.,MERINGOLO F.,NERI MG.MONTESISSA L., RAIMONDI A. In vitro sensitivity of Human Gastric Cancer Cells( HGC-27) to Helicobacter pylori cytotoxin. Scand. J. Gastroenterol. 12:1228-1234,2003. PESSINA A., GIULIANI A., CROERA C., FOTI P., MASCOLO L. GAGLIARDI G. NERI MG. Selection of a WEHI-3B leukemia cell subclone resistant to inhibition by cholera toxin. Mol.Cell Biochem., 233,19-26,2002. PESSINA A., GAGLIARDI G.,CROERA C.FOTI P.,DASSI C.BRAMBILLA P.,NERI MG..Secretion of basic fibroblast growth factor (FGF-2) by WEHI-3B myelomonocitic leukemia cells. Growth Factors, 20,121-129,2002. PESSINA A.,RAIMONDI A:;CROERA C:, ACCHINI M:,MINEO E.,FOTI P:,NERI MG: Altered DNA cleavage activity of topoisomerase II from WEHI-3B leukemia cells resistant to ciprofloxacin. Anti-Cancer Drugs,12, 441-451,2001 PESSINA A,RAIMONDI A.CERRI A. PICCIRILLO M, NERI MG, CROERA C.,FOTI P.,BERTI E. High sensitivity of human epidermal keratinocytes (HaCaT) to topoisomerase inhibitors. Cell Proliferation,34,243-252,2001. PESSINA A., ALBELLA B., BUEREN J.,.BRANTOM P., CASATI S.,.CROERA C., GAGLIARDI G., GRIBALDO L, FOTI P., PARCHMENT R., PARENT-MASSIN D., SCHOETERS G., SIBIRIL Y.,VAN DEN HEUVEL Prevalidation of a model for predicting acute neutropenia by Colony Forming Unit- Granulocyte/Macrophage CFU-GM) assay Toxicology in Vitro, 15,729-740,2001. GRIBALDO L, MALERBA I.,COLLOTTA A.,CASTI S.,PESSINA A.. Inhibition of CFGU-e/BFU-E by 3 -azido- 3 -deoxythymidine,chlorpropamide and protoporphirin IX zinc (II): a comparison between direct exposure of progenitor cells and long-term exposure of bone marrow. Toxicological Sciences 58, 96-101,2000. PESSINA A.,PICCIRILLO M.,MINEO E.,CATALANI P.,GRIBALDO L., MARAFANTE E., NERI MG.,RAIMONDI A. Role of SR-4987 stromal cells in the modulation of Doxorubicin toxicity to in vitro granulocyte-macrophage progenitors (GM-CFU). Life Sciences, 65,513-523,1999. 6

PESSINA A., ROSSONI L.,PICCIRILLO M.,SALA G.,NERI MG.. Preliminary study on in vitro activity and cytotoxicity on cell cultures of a new polyene antifungal molecule (SPA-S-843). Eur. J. Pharmac. Biopharmac. 47,179-184,1999. GRIBALDO L.,CASATI S.,CASTOLDI A., PESSINA A.Comparison of In Vitro drug sensitivity of Human Granulocyte-Macrophage progenitors from two different origins:umbilical cord blood and bone marrow. Exp. Hematol., 27,1593-1598,1999. FULL PAPERS BIGI G.,PESSINA A- Immunità e tumori. Sapere,753,24-29,1972.. CLERICI E.,GAROTTA G.,PORTA C.,PESSINA A.,VILLA ML. Immunological aspects of amyloydosis. Isr.J.Med.Sc., 9,881-887,1973. PORTA C.,PESSINA.A. Complemento e infiammazione. Sapere, 757,28-30,1973. PESSINA A.,BRAMBILLA P.,BALZARIN D. Inhibition of Ehrlich ascites carcinoma (EAC) growth by carbonyl iron. Experientia,34,1518-1519,1978. PESSINA A.,BRAMBILLA P.,MOCARELLI P. Surface antigen on Ehrlich Ascites Tumor Cells. Biomedicine.,33, 105-109,1980. PESSINA A.,ERIDANI S., BRAMBILLA P., CATTORETTI G, MAROCCHI A., MOCARELLI P. Effect of tumor related factors on the in vivo and in vitro colony forming ability of normal mouse marrow cells. Neoplasma,28,541-548,1981 PESSINA A.,BRAMBILLA P.,VILLA S.,MAROCCHI A.,MOCARELLI P.. Factors produced by macrophages and tumor cells: influence on the granulocytic precursor cells(cfu-c) in normal and tumor bearing mice. J.Cancer Res.Clin.Oncol.,102,235-244,1982. PESSINA A.,BRAMBILLA P.,VILLA S.,MOCARELLI P.. CFU-s and CFU-C proliferation after treatment of normal bone marrow cells with tumoral ascitic fluid. Oncology, 39,391-395,1982. PESSINA A.,NERI M.G.,MUSCHIATO A..Effect of heat-labile enterotoxin (LT) produced by Escherichia coli on in vitro cell proliferation. Experientia.,38,1056-1057,1982. SIRCHIA G.,ROSSO DI SAN SECONDO V.E.M.,TEDESCO F.,FORTIS C.,ALCINI D.,GIOVANETTI A.M.,GUAZZOTTI L.,ZANUSSI C.,SCORZA R.,FABIO G.,BONARA P.,MERONI P.L.,SABBADINI M.G.,VANOLI M., PETTENATI C.,MOCARELLI P.,PESSINA A., BRAMBILLA P.,MAROCCHI A., CAREDDU P.,BARDARE M.,CORONA F.,CHIAPPINO G.,NAVA C.,MEREGALLI G.,GARATTINI S., SPREAFICO F.,VECCHI A.,MANTOVANI A.,MARUBINI E.,MILANI S.. Exposure to TCDD:Immunologic Effects. In:Plans for clinical and epidemiologic follow-up after area-wide chemical contamination. Proc.Int.Workshop,Washington,D.C.,March 1980.Eds.L. Dardanoni, R.W.Miller. Natl.Acad.Press,Washington M arch 1982. Pagg.234-264. PESSINA A.,NERI M.G.,MUSCHIATO A.,RAIMONDI A.. Inhibition of granulocytic-macrophagic precursor cells (CFU-C) by heat-labile enterotoxin (LT) produced by Escherichia coli. Biomed. Pharmacother.37,447-452,1983. PESSINA A.,NERI M.G.. Factors affecting the proliferation of a murine T-cell lymphoma. Chemioterapia,S5,459-460,1983. PESSINA A.,BRAMBILLA P.,MOCARELLI P..Modulation of EL-4 mouse lymphoma cell proliferation by macrophages and tumor related factors. Blut 49,45-51,1984. 7

SEZZANO P.,RAIMONDI A.,PESSINA A.,NERI M.G..Isolation and partial chracterization of temperate bacteriophages from enteropathogenic strains of Escherichia coli O111:K58. Acta Virologica,29,73-78,1985. PESSINA A.,BRAMBILLA P.,NERI M.G.,MOCARELLI P..Production of colony stimulating factor by EL-4 lymphoma cells stimulated with phytohemoagglutinin. Int. J. Immunopharmac., 7,549-553,1985. RAIMONDI S.,DONGHI R.,MONTAGUTI A.,PESSINA A.,DEHO' G..Analysis of spontaneous deletion mutants of satellite bacteriophage P4. J.Virol.,54,233-235,1985. PESSINA A.,NERI M.G..Colony stimulating factor produced by T-lymphoma cells. Chemioterapia,S2,1172-1173,1985. PESSINA A.,NERI M.G.,MUSCHIATO A.,BRAMBILLA P.,MAROCCHI A. MOCARELLI P.. Colony stimulating factor produced by murine adrenocortical tumor cells. J.Natl.Cancer Inst.,76,1095-1099,1986. PESSINA A.,MUSCHIATO A.,COLOMBO M.,NERI M.G..Escherichia coli heat-labile enterotoxin:biological activity of crude filtrate and fractions isolated by gel chromatography. Chemioterapia, S2,46-48,1987. NERI M.G.,OTTOLENGHI A.,PESSINA A.,DE CHIARA A., MAGLIANO E..Detection of enterotoxigenic strains of E.coli in children with acute diarrhea. Chemioterapia,S2,44-45,1987. PESSINA A.,MUSCHIATO A.,NERI M.G..Isolation of a colony stimulating factor produced by L1210 murine leukemia cells. Blut.,55,499-504,1987. PESSINA A.,MATTINA R.,COCUZZA C.E.. Attività biologica dei chinoloni sulle cellule procariote ed eucariote. Farmaci & Terapia,4,185-190,1987. NERI M.G.,PESSINA A.,OTTOLENGHI A.,COCUZZA G.. Enterobatteri produttori di tossina termolabile nelle diarree acute. L'Igiene Moderna,89,602-611,1988. PESSINA A.,NERI M.G.,IANNETTA M.,MINEO E.. Effect of fluorinated quinolones on heat-labile toxin production by Escherichia coli. J.Chemother.,S4,138-139,1989. PESSINA A.,NERI M.G.,MINEO E.,COCUZZA C.E..Effect of quinolones on the production of colony stimulating factors by macrophages. J.Chemother.S4,419-420,1989. PESSINA A.,NERI M.G.,MUSCHIATO A.,MINEO E.,COCUZZA G..Effect of fluoroquinolones on the in vitro proliferation of myeloid precursor cells. J.Antimicrob. Chemother.,24,203-208,1989. PESSINA A.. Citochine: quale futuro in campo diagnostico? Diagnosis,1,113-116,1989. PESSINA A.,MINEO E.,MASSERINI M.,NERI M.G.,COCUZZA C.E.. Inhibition of murine leukemia (WEHI-3B and L1210) proliferation by cholera toxin B subunit. Biochim. Bioph. Acta.1013,206-211,1989. PESSINA A.,NERI MG.,GRIBALDO L.,MINEO E.,COCUZZA G.. Sensibilità in vitro di cellule leucemiche e precursori mieloidi murini a fluorochinoloni. J.Chemother.,S2,583-585,1990. PESSINA A.,MINEO E.,NERI M.G.,COCUZZA G..In vitro effect of fluoroquinolones on macrophages response to LPS stimulation and phagocytosis. J.Chemother.,S4,542-544,1991. PESSINA A.,MINEO E.,GRIBALDO L.,MANCINA G.,NERI MG.. Lack of in vitro antiviral activity of fluoroquinolones against herpes simplex virus type 2. Arch.Virol.,122,263-269,1992. PESSINA A., MINEO E.,NERI MG.,GRIBALDO L.,COLOMBO R., BRAMBILLA P.,ZALESKIS G.. Establishment and characterization of a new murine cell line (SR-4987) derived from marrow stromal cells. Cytotechnology.,8,93-102,1992. PESSINA A. Dimmi cosa fai e ti dirò chi sei. Editoriale Diagnosis,5,201,1992. 8

PESSINA A.,GRIBALDO L.,MINEO E.,NERI MG.. Effect of fluoroquinolones on the in vitro production of tumor necrosis factor(tnf) by P388D1 cells. J.Chemother.,5,562-564,1993 PESSINA A.,MINEO E.,GRIBALDO L.,MANCINA G.,NERI MG.,MORAN E.,CLEARY I., CLYNES M. Susceptibility of leukemia cell lines to quinolones and induction of resistance to ciprofloxacin in WEHI-3B(D+) leukemia cells. Cancer J.,6,291-297,1993. PESSINA A. Topoisomerase I in multiple drug resistance. Cytotechnology, 12,127-135,1993. PESSINA A.,GRIBALDO L.,MINEO E.,NERI MG.. In vitro short-term and long-term cytotoxicity of fluoroquinolones on murine cell lines. Ind. J. Exp. Biol.,32,113-118,1994. RAIMONDI A.,PESSINA A., COCUZZA G. Outer membrane permeability of Serratia marcescens to meropenem and imipenem. J.Chemother.6,363-367,1995. PESSINA A.,RAIMONDI A., NERI MG. Different biological conditions influencing bacterial adherence assay. J.Chemother.,7,8-11,1995 PESSINA A.,ZALESKIS G.,MINEO E.,CERRI A., NERI MG. Expression of CD antigen on SR-4987 murine marrow stromal cells. J.Exp. Clin. Cancer Res. 14,197-198,1995. NERI M.G.,MINEO E.,PICCIRILLO M., PESSINA A.. Attività microbicida di benzalconio cloruro-alcansolfonato sodico su microorganismi di interesse veterinario. Ingegneria Alimentare, 6,25-29,1995. GIULIANI A.,CALAPPI E., MINEO E.,NERI MG.,MASSERINI M., GALLINA A.,PESSINA A. The different inhibiting effect of cholera toxin on two leukemia cell lines does not correlate with their toxin binding capacity. Mol.Cell.Biochem,152,103-112,1995 PESSINA A. Coltivatori di cellule in vitro. Kos,119/120,23-25,1995. PESSINA A.,PICCIRILLO M.,MINEO E.,TASSI E.,BRAMBILLA P., NERI MG.. A simple quantitative bioassay for basic fibroblast growth factor using SR-4987 cells as target. Meth. Mol. Cell. Biol.,5,230-236,1995. RAIMONDI A.,PESSINA A., NERI MG.. Loss of Porins Following Carbapenem-Resistance Selection and Adherence Modification in Enterobacteria. J.Chemother. 7,171-174,1995. GRIBALDO L.,BUEREN J.,DELDAR A.,HOKLAND P.,MEREDITH C.,MONETA D., MOSESSO P., PARCHMENT R., PARENT-MASSIN D.,PESSINA A., SAN ROMAN J., SCHOETERS G.. The use of in vitro systems for evaluating haematotoxicity. ATLA, 24,211-231,1996 PESSINA A.,NERI MG.,MINEO E.,PICCIRILLO M.,GRIBALDO L.,BRAMBILLA P.,ZALESKIS G.,UJHAZY P.. Expression of B cell markers on SR-4987 cells derived from murine bone marrow stroma. Exp. Hematol. 25,536-541,1997. GRIBALDO L.,PICCIRILLO M.,CASATI S.,COLLOTTA A.,MINEO E.,PESSINA A.. Drug sensitivity of granulocyte-macrophage precursors (GM-CFU) from fresh murine bone marrow and from long- term bone marrow cultures. Toxicology In Vitro, 12, 39-45, 1998. PESSINA A.,MINEO E.,NERI MG.,PICCIRILLO M.,VALORE L.,GIULIANI A..SR-4987 and L1210 cell lines :two models in which the cholera toxin susceptibility does not correlate with camp accumulationa and ganglioside content. Cell.Mol.Biol.,44,933-940,1998. PARCHMENT R.E, PESSINA A. Topoisomerase I inhibitors and drug resistance. Cytotechnology, 27, 149-164,1998. PESSINA A.,PICCIRILLO M.,MINEO E.,CATALANI P.,GRIBALçDO L.,MARAFANTE E., NERI MG.,RAIMONDI A. Role of SR-4987 stromal cells in the modulation of Doxorubicin toxicity to in vitro granulocytemacrophage progenitors (GM-CFU). Life Sciences, 65,513-523,1999. PESSINA A. Appunti di Viaggio. Un ricercatore di fronte ai dati della realtà. Emmeciquadro,10,25-30,1999. 9

PESSINA A., ROSSONI L.,PICCIRILLO M.,SALA G.,NERI MG.. Preliminary study on in vitro activity and cytotoxicity on cell cultures of a new polyene antifungal molecule (SPA-S-843). Eur. J. Pharmac. Biopharmac. 47,179-184,1999. GRIBALDO L.,CASATI S.,CASTOLDI A., PESSINA A.Comparison of In Vitro drug sensitivity of Human Granulocyte-Macrophage progenitors from two different origins:umbilical cord blood and bone marrow. Exp. Hematol., 27,1593-1598,1999. GRIBALDO L, MALERBA I.,COLLOTTA A.,CASTI S.,PESSINA A.. Inhibition of CFGU-e/BFU-E by 3 -azido- 3 - deoxythymidine,chlorpropamide and protoporphirin IX zinc (II): a comparison between direct exposure of progenitor cells and long-term exposure of bone marrow. Toxicological Sciences 58, 96-101,2000. PESSINA A.,RAIMONDI A:;CROERA C:, ACCHINI M:,MINEO E.,FOTI P:,NERI MG:: Altered DNA cleavage activity of topoisomerase II from WEHI-3B leukemia cells resistantto ciprofloxacin. Anti-Cancer Drugs,12, 441-451,2001 PESSINA A,RAIMONDI A.CERRI A. PICCIRILLO M, NERI MG, CROERA C.,FOTI sensitivity of human epidermal keratinocytes (HaCaT) to topoisomerase inhibitors. Cell Proliferation,34,243-252,2001. P.,BERTI E. High PESSINA A., ALBELLA B., BUEREN J.,.BRANTOM P., CASATI S.,.CROERA C., GAGLIARDI G., GRIBALDO L, FOTI P., PARCHMENT R., PARENT-MASSIN D., SCHOETERS G., SIBIRIL Y.,VAN DEN HEUVEL Prevalidation of a model for predicting acute neutropenia by Colony Forming Unit-Granulocyte/Macrophage CFU-GM) assay Toxicology in Vitro, 15,729-740,2001. PESSINA A., GIULIANI A., CROERA C., FOTI P., MASCOLO L. GAGLIARDI G. NERI MG. Selection of a WEHI-3B leukemia cell subclone resistant to inhibition by cholera toxin. Mol.Cell Biochem., 233,19-26,2002. PESSINA A., GAGLIARDI G.,CROERA C.FOTI P.,DASSI C.BRAMBILLA P.,NERI MG.. Secretion of basic fibroblast growth factor (FGF-2) by WEHI-3B myelomonocitic leukemia cells. Growth Factors, 20,121-129,2002. PESSINA A., ALBELLA B., BAYO M., BUEREN J.,.BRANTOM P., CASATI S., CROERA C., PARCHMENT R., PARENT-MASSIN D., SCHOETERS G., SIBIRIL Y.,VAN DEN HEUVEL R.,.GRIBALDO L. In vitro tests for haematotoxicity: Prediction of drug induced Myelosuppression by the CFU-GM assay. ATLA (Altern. Lab. Anim) 30 S2:75-79, 2002. RAIMONDI A.,SISTO F.,RIZZARDI R., PESSINA A.,TICOZZI R.,NERI MG.. Sequenza di due forme alleliche del gene di beta-lattamasi cromosomiale di S.marcescens. Effetto della loro espressione sulla sensibilità ad antibioticibetalattamici di ospiti Trasformati GIMNOC,Vol VI:53-56,2002. PESSINA A., ALBELLA B., BAYO M., BUEREN J.,.BRANTOM P., CASATI S.,.CROERA C.,GAGLIARDI G FOTI P, PARCHMENT R., PARENT-MASSIN D.,SCHOETERS G., SIBIRIL Y.,VAN DEN HEUVEL R.,.GRIBALDO L.Application of the CFU-GM assay to predict acute drug-induced neutropenia:an international blind trial to validate a prediction model for the maximum tolerated dose(mtd) of myelosuppressive xenobiotics. Toxicological Sciences, 75,355-367,2003. ROSEEUW E.,COESSENS V.,BALAZUC AM.,LAGRANDERIE M.,CHAVAROT P.,PESSINA A., NERI MG., SCHACHT E.,MARCHAL G., DOMURADO D..Synthesis, degradation and antimicrobial properties of targeted macromolecular prodrugs ofnorfloxacin. Antimicrob. Agents Chemother.,47,3435-3441,2003. PESSINA A., BAYO M.,CROERA C.,MERINGOLO F.,NERI MG.MONTESISSA L.,RAIMONDI A. In vitro sensitivity of Human Gastric Cancer Cells( HGC-27) to Helicobacter pylori cytotoxin. Scand. J. Gastroenterol. 12:1228-1234,2003. PESSINA A. Le cellule staminali. Ricerca, problemi applicazioni. Emmeciquadro 17:16-24,2003. PESSINA A.,GIULIANI A.,CROERA C.,GAGLIARDI G.,NERI. MG. Different response to "in vitro" cholera toxin treatment by three murine cell models. L'Igiene Moderna 120:305-321,2003. 10

PESSINA A., CROERA C., BAYO M., MALERBA I., PASSARDI L., CAVICCHINI L., NERI M.G., GRIBALDO L. A methylcellulose microculture assay for the in vitro assessment of drug toxicity on granulocyte- macrophage progenitors (CFU-GM). ATLA 32:17-23, 2004 PESSINA A.,ELETTI B:,CROERA C.,SAVALLI N.,DIODOVICH C.,GRIBALDO L..Pancreas developing markers expressed on human mononucleated umbilical cord blood cells.biochem Biophys. Res. Comm. 323:315-322,2004 PESSINA A., MALERBA I., GRIBALDO L. Haematotoxicity testing by cell clonogenic assay in drug development and preclinical trials Curr.Pharmaceut.Design 11:1055-1065,2005. PESSINA A.,TURLIZZI E.,BONOMI A. et al. In vitro toxicity of clozapine,olanzapine and quetiapine on granulocytemacrophage progenitors(gm-cfu).pharmacopsychiatry,39,20-22,2006. PESSINA A.,CROERA C.,SAVALLI N. et al. Bcl-2 down modulation in WEHI-3B/CTRES cells resistant to Cholera Toxin (CT)-induced apoptosis. Cell Res. 16:306-312,2006 PESSINA A. and GRIBALDO L. The key role of adult stem cells: therapeutic perspectives. Opin.,22,2287-2300,2006. Curr. Med. Res. PESSINA A.,BONOMI A.CASATI S. et al. Mitochondrial function, apoptosis and cell-cycle delay in the WEHI-3B leukemia cell line and its variant ciprofloxacin-resistant WEHI-3B/CPX. Cell Prolif.,40,568-579,2007. PESSINA A.,BONOMI A.,BAGLIO C. et al. Microbiological Risk Assessment In Stem Cell Manipulation. Crit.Rev.Microbiol, 34:1-12,2008. PESSINA A.,PARENT-MASSIN D., ALBELLA B.et al. Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs. Toxicology in Vitro, 23:194-200,2009. PESSINA A.,BONOMI A.,BAGLIO C.,CAVICCHINI L.,GRIBALDO Refinement and optimisation of the rat CFU- GM assay to use cryopreserved bone marrow cells for in vitro toxicology application. Altern.To Lab.Animals (ATLA) 37: 417-425,2009. PESSINA A.,BONOMI A.,COCCÈ V. et al. Assessment of human herpesvirus-6 infection in cells ex vivo expanded for clinical use.transpl Infect Dis T.11 : 491-496,2009. mesenchymal stromal PESSINA A.,BONOMI A.,CAVICCHINI L. et al. Prevalidation of Rat GM-CFU Assay for In Vitro Toxicology Application. Altern.To Lab.Animals (ATLA) 38:105-117,2010. PESSINA A., BONOMI A.,SISTO F. er al. CD45+/CD133+ positive cells expanded from umbilical cord blood expressing pdx-1 and markers of pluripotency. Cell Biol. Int.34:783-790,2010. PESSINA A. Cellule staminali pluripotenti. Le prospettive delle ipsc restano problematiche. Emmeciquadro 38: 27-30,2010. LULLI M, DI GESUALDO F.,WITORT E.,PESSINA A.,CAPACCIOLI S. Cell death: physiopathological and therapeutic implications. Cell Death Dis. 1: e30; doi:10.1038/cddis.2010.8 PESSINA A.,SISTO F.,COCCE V. et al. A mesenchymal stromal cell line resistant to paclitaxel that spontaneously differentiates into Osteoblast-like cells. Cell Biol Toxicol 27:169-180,2011. PESSINA A., BONOMI A., COCCE V. et al. Mesenchimal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PloSONE, 6, Issue 12, e28321,2011. PESSINA A, COCCÈ V,.BONOMI A.,CAVICCHINI L., SISTO F., FERRARI M., NAVONE S., MARFIA G., PARATI E., ALESSANDRI G. Human Skin-Derived Fibroblasts Acquire In Vitro Anti-Tumor Potential after Priming with Paclitaxel. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 523-30. 11

PESSINA A, COCCÈ V,. PASCUCCI L.,BONOMI A.,CAVICCHINI L., SISTO F., FERRARI M.,CIUSANI E.,NAVONE S., MARFIA G., BENETTI A. CECCARELLI P.,PARATI E., ALESSANDRI G. Mesenchymal stromal cells primed with Paclitaxel attract and kill leukemia cells, inhibit angiogenesis and improve survival of leukemiabearing mice. British Journal of Haematology, 2013, 160, 766 778 BONOMI A., COCCÈ V,.CAVICCHINI L., SISTO F., DOSSENA M.,BALZARINI P. PORTOLIANI N.,CIUSANI E.,PARATI E., ALESSANDRI G. PESSINA A. Adipose-tissue-derived stromal cells primed in vitro with paclitaxel acquires anti-tumor activity. Int. J.Immunopath. Pharmacol. 2013,26,33-42. L.DE GIROLAMO, E.LUCARELLI, G. ALESSANDRI, M.A. AVANZINI, M.E. BERNARDO, E.BIAGI, A.T.BRINI, G.D AMICO, F.FAGIOLI, I.FERRERO, F.LOCATELLI, R.MACCARIO, M.MARAZZI, O.PAROLINI, A. PESSINA*,M.L.TORRE * Italian Mesenchymal Stem Cell Group (GISM). Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy.Curr. Pharmaceut. Des. 2013,19,2459-73. CHAPTERS OF BOOKS CLERICI E.,GAROTTA G.,PORTA C.,BIGI G.,PESSINA A. Reattività immunologica nel feto e nel neonato. In: Corso di perfezionamento in metodiche immunologiche e Simposio sui problemi di immunologia di interesse pediatrico. Ed. Piccin,Padova. Pagg 263-286,1977. CLERICI E.,PORTA C.,BIGI G.,GAROTTA G.,PESSINA A. Tecniche per la quantizzazione delle cellule staminali dei B e T linfociti e metodi di studio dell'anticorpopoiesi "in vitro".in: Corso di perfezionamento in metodiche immunologiche e Simposio sui problemi di immunologia di interesse pediatrico. Ed. Piccin,Padova. Pagg. 66-83,1977. PESSINA A. I colony stimulating factors: regolatori della proliferazione e della differenziazione dei precursori granulo- macrofagico. Dispensa per la "Scuola di Specializzazione in Farmacologia ",Facolta di Farmacia,1983. PESSINA A.,MUSCHIATO A.,NERI M.G.. Isolation of colony stimulating factors produced in vitro by murine adrenal tumor cells. In : Biological Regulation of Cell Proliferation. Baserga R.,Foa P.,Metcalf D.,Polli E.E.,Eds. Raven Press,New York,1986. Vol. 34,pagg 191-194. PESSINA A.. The Granulocyte/Macrophage Colony Forming Unit Assy. In:Animal Cell Culture Techniques. Ed.M. Clynes,pp 217-229,Springer-Verlag,, Heidelberg 1998 PESSINA A., ALBELLA B., BUEREN J.,.BRANTOM P., CASATI S., CORRAO G., GRIBALDO L., PARCHMENT R.,PARENT-MASSIN D.,PICCIRILLO M.,RIO B.,SACCHI S.,SCHOETERS G.,Van Den HEUVEL R.. Method developement for a prevalidation study of in vitro GM-CFU assay for predicting myelotoxicity.. In: Progress in the reduction, refinement and replacement of animal experimentation. Balls M,van Zeller A-M, Halder M (eds). Amsterdam: Elsevier, 2000 Pages 679-691. PESSINA A.,BONOMI A. CFU-GM assay for evaluation of drug Myelotoxic Activity Curr.Prot.Toxicol. 34:20.2.1-20.2.18, Eds. John Wiley & Sons,Inc., 2007. PESSINA A.,BONOMI A. Prediction of potential drug myelotoxicity by in vitro assays on haematopoietic progenitors. In Methods in Bioengineering Tim Maguire and Eric Novik Eds, Artech House Boston-London. Pages 115-131,2010. PESSINA A,.BONOMI A., PARATI E., PALLINI R., ALESSANDRI G. Primed mesenchymal stromal cells for cancer therapy. In Stem Cell Therapeutics for Cancer. Ed Khalid Shah. John Wiley & Sons, Inc., USA.( 2013, In Press) PESSINA A., BONOMI A., CIUSANI E., PASCUCCI L.,PARATI E., ALESSANDRI G. Paclitaxel: Biosynthesis, Mechanisms of Action and Clinical Uses''in Mesenchymal stromal cells used for carrying and delivering Paclitaxel NOVA SCIENCE PUBLISHERS,INC.Hauppauge, NY 11788-3619, USA ( 2013 in press) ACTA, PROCEEDINGS AND EXTENDED ABSTRACTS 12

MOCARELLI P.,VILLA ML.,PESSINA A.,BIGI G.,CLERICI E. Meccanismi cellulari della immunodepressione da tumore.rendiconti Acc. Naz. Lincei,XLIX,446-451,1970. PESSINA A.,PORTA C.Lymphoid repopulation and immune response in X-irradiated mice. Atti Simposio Internaz.Ematologia. Ed.Viscontea, Milano.pagg. 5-12,1975. ERIDANI S.,PESSINA A.,BRAMBILLA P.,PERRONE G.,MOCARELLI P. Influenza di fattori di origine neoplastica sulla ripopolazione esogena di CFU-s nel topo. In: Lo studio delle cellule staminali in vitro. Ed.M.A.Brunelli et al.,esculapio,bologna. Pag.267-271,1976. SEZZANO P.,RAIMONDI A.,GHIDONI G.,PESSINA A.,NERI MG..Caratteristiche di batteriofagi temperati isolati da E.coli enteropatogeni di differenti sierogruppi. Atti XX ongr.naz.microbiologia..brescia-gardone, Maggio 1983. Pagg.542-543. SEZZANO P.,RAIMONDI A.,PESSINA A.,NERI MG.. Fattori di patogenicita e lisogenia in E.coli O111:K58.Atti XX Congr.Naz. Microbiologia..Brescia-Gardone, Maggio 1983.Pagg.307-308. RAIMONDI A.,SEZZANO P.,PESSINA A.,DONGHI R.,DEHO' G.. Isolamento e caratterizzazione di mutanti delezione del batteriofago satellite P4. Atti XX Congr.Naz.Microbiologia..Brescia-Gardone, Maggio 1983. Pagg.234-235. PESSINA A.,BRAMBILLA P.,MOCARELLI P.,NERI MG.. Conditioned media from tumoral and transformed cell cultures:biological acttivity on stem cell differentiation. Proc.13th Int.Congress Chemother.,K.H.Spitzy and K.Karrer Eds.,,Vienna Settembre1983. PESSINA A.,MUSCHIATO A.,NERI M.G.. Production of colony stimulating factors by L1210 leukemia cells. In:"In vitro control of cell differentiation",ed.rizzoli C.,Bologna,1985. Pag.18. PESSINA A.,MUSCHIATO A.,NERI M.G.. Modulazione dell'attività di colony stimulating factors da parte di tossina termolabile di E.coli. Atti XXI Congr.Naz.Soc.It.Microbiologia,Roma,Dicembre 1985. Pag.439. RONDININI G.,PESSINA A.,NERI M.G.,OTTOGALLI G.. Ricerca di enterobatteri produttori di tossina termolabile in prodotti lattiero-caseario. Atti XXI Congr.Naz.Soc.It.Microbiologia,Roma Dicembre 1985. Pag.549. PESSINA A.,MUSCHIATO A.,NERI M.G.. Isolation of colony stimulating factors produced in vitro by murine adrenal tumor cells. Commun. to the "Int.Symposium on Biological Regulation of cell proliferation.milan, Marzo, 1986. Pag.115. MOCARELLI P.,BRAMBILLA P.,MAROCCHI A.,PESSINA A.,COLOMBO L.,TRAMACERE P.L.,SARTO C.. Purification of GM-CSF from the myoepithelioma cell line SGC-A. Commun. to the "Int. Symposium on Biological Regulation of cell proliferation. Milano Marzo,1986.Pag.87. PESSINA A.,NERI M.G.,MUSCHIATO A.,COCUZZA G.. Effetto della pefloxacina sulla proliferazione di precursori mieloidi. Atti XV Congr.Naz. Soc. It.Chemioterapia. Pesaro-Urbino Giugno 1987. Ed.CIC srl,roma.pag-31-33. PESSINA A.,NERI M.G.,MINEO E.,COCUZZA G.. Effect of lomefloxacin (LMFX) and ciprofloxacin(cpfx) on the in vitro proliferation of granulocyte-macrophage precursors. Proc. 16th Int.Congr.Chemother.,Jerusalem June 1989.Pag.3131-3132. PESSINA A.,MINEO E.,GRIBALDO L.,NERI MG. Cytotoxicity of fluoroquinolones on murine cell lines. Proc."5th Int. Symposum on Clinical and Environmental Microbiology", Brescia,October 1991.Pagg.55-56. ABSTRACTS AND COMMUNICATIONS TO CONGRESS ( about 100 not reported ) 13